120 related articles for article (PubMed ID: 38801884)
21. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
[TBL] [Abstract][Full Text] [Related]
23. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
[TBL] [Abstract][Full Text] [Related]
24. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
25. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
[TBL] [Abstract][Full Text] [Related]
26. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
Hastak K; Bhutra S; Parry R; Ford JM
Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
[TBL] [Abstract][Full Text] [Related]
27. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
[TBL] [Abstract][Full Text] [Related]
28. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
30. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
[TBL] [Abstract][Full Text] [Related]
31. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Kuo ML; Hwang HS; Sosnay PR; Kunugi KA; Kinsella TJ
Cancer J; 2003; 9(4):277-85. PubMed ID: 12967138
[TBL] [Abstract][Full Text] [Related]
35. Progesterone and DNA damage encourage uterine cell proliferation and decidualization through up-regulating ribonucleotide reductase 2 expression during early pregnancy in mice.
Lei W; Feng XH; Deng WB; Ni H; Zhang ZR; Jia B; Yang XL; Wang TS; Liu JL; Su RW; Liang XH; Qi QR; Yang ZM
J Biol Chem; 2012 May; 287(19):15174-92. PubMed ID: 22403396
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.
Zhang K; Hu S; Wu J; Chen L; Lu J; Wang X; Liu X; Zhou B; Yen Y
Mol Cancer; 2009 Feb; 8():11. PubMed ID: 19250552
[TBL] [Abstract][Full Text] [Related]
37. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.
Han J; Hu J; Sun F; Bian H; Tang B; Fang X
Mol Cell Biochem; 2021 Feb; 476(2):689-698. PubMed ID: 33125611
[TBL] [Abstract][Full Text] [Related]
39. A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.
Specks J; Lecona E; Lopez-Contreras AJ; Fernandez-Capetillo O
Mol Cell Biol; 2015 Sep; 35(17):2910-7. PubMed ID: 26077802
[TBL] [Abstract][Full Text] [Related]
40. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]